from mental health disorders has beenincreasing and studies havebeencarried out to evaluate theimpact of pharmacist interventions in thispopulation. In 2003,Finley et al," conducted a systematic review examining the impact of clinical pharmacists on the careandoutcomes of patients withmental disorders including, among other diagnoses, schizophrenia, depression, and behavioral disturbances. The pharmacist interventions described in thereview included drugmonitoring, treatment recommendations, patient education, drug management,andeducation to providers on prescribing patterns. The results of this workindicated a positive effectof pharmacist interventions in patients with mental health problems, although there were several sources of heterogeneity related to the study design, patient populations, measured outcomes, and treatmentsettings.Furthermore,since this review was published, more researchhas been conducted on this issue' , therefore, theseresults needto be updated.
More recent systematic reviews have shown that multidisciplinary strategies for the management of patients with mentalhealth problems in primarycare have a positiveeffect on antidepressant use and depressive outcomes.":" These studies concluded that interventions conducted by case managers with a specific mental health background were more effective in improving symptomoutcomesthan those conducted by case managers withouta specificmental health background, such as pharmacists. However, no significant differences were detectedwhen the outcomeassessedwas antidepressant use. Furthermore, in these analyses pharmacists were grouped with other health professionals,so their specificcontribution to the results is difficult to determine. Overall, most of the literature in this field did not appear to show statistically significantdifferences betweenintervention and controlgroupsand seemed to be inconclusive. Wetherefore conducted a meta-analysis to increase the power of the study and to try to improveeffect size estimate.
In general, interventions conducted by pharmacists are usuallyfocused on medication; consequently, adherence is the primaryoutcome in most of these studies.For this reason we decidedto focus our reviewon adherence improvement. Furthermore, in patientswith depression, it has been stated that there is a significant positive association between antidepressant use and improved depression outcomesp, 18 The objective of this study was to systematically review randomizedcontrolledtrials (RCTs) evaluating the impact of pharmacist interventions on outpatients with regard to improvement of adherence to antidepressants when a depressive disorderwas being treated.
Methods
We followed the PRISMA guidelines for reporting meta-analyses."
LITERATURE SEARCH
We performed a systematicreview of the published literaturefor RCTsevaluating the impactof pharmacist interventions on the improvement of adherence to antidepressant pharmacologic treatment of outpatients with depressive disorder (major depressive disorder and dysthymic disorder) according to Diagnostic and Statistical Manual ofMentalDisorders (DSM) or International Classification of Diseasescriteria.In order to identify all articles involving interventions intended to improve use of antidepressants, the databases were searched separately by 2 investigators (AP and MRV). Literature searcheswere completed from inception to April 2010, without language restrictions, through MEDLINE, the Cochrane Central Register of Controlled Trialsdatabase, the Institute for Scientific Information Web of Knowledge, and the Spanish National Research Council databases.
The search strategy used was: [("Pharmaceutical Services"[MeSH] OR pharmac* OR "pharmaceutical intervention" OR "pharmacy counsel*" OR "pharmacy-based coaching")AND ("Depressive Disorder"[MeSH] OR "depression" OR "Antidepressive Agents"[MeSH] OR "antidepressant*") AND ("
Abstracts of all citations were obtained for study selection.Citationindicesand reference lists of retrieved articles were checked for additional studies not identified in the originaldatabase search.Expertinformants from the pharmaceuticalindustry and the School of Pharmacy (University of Barcelona) were consulted to retrieve grey literature (such as unpublished reports and conference abstracts).
STUDYSELECTION
Studies were screenedfor inclusionby reviewing the title, the publishedabstract, and the full articlewhere necessary. First selection was made in duplicate (AFS and MRV). The final screening,which reviewed full text articles, was performed by 2 researchers (ASB and MRV). One of the researchers (ASB) was blindedto the names of the authors of the articles and the journals in which they were published. In the case of disagreement, a third researcher(APS)was consulted.
We included RCTs with ambulatory patientsdiagnosed using a validated psychiatric interview or a clinical diagnosis for a mooddisorderand who were initiating or maintaining treatment withantidepressants. No restriction by type of antidepressant medication was applied.Nor were restrictions imposedwith respectto age, sex, or ethnicity. Interventions takenintoaccount included educational messages and counseling,monitoring and medication dosage adjustment,and management of adverseeffects.Our definitionof interven-40 • The Annals of Pharmacotherapy • 2011 January, Volume 45 theannals.com tionexcluded all research in which the pharmacist's rolewas focused onlyon the review of medication patterns (ie,detection of medication-related problems, such as drug interactions,without a subsequent intervention delivered to the patientto solve theproblems). As theintervention should be applieddirectly to the patient, articles evaluating the effects of pharmacist intervention in institutions, physicians, or families were excluded. Articles were rejected if the study was conductedin an acuteinpatient facility or hospital, or if it was a multidisciplinary modelin whichthe role of the pharmacist was not wellestablished. Nevertheless, therewas no restrictionregarding the setting in whichthe intervention was performed, so thatcommunity pharmacies or pharmacy services in hospitals or primary carecenters wereincluded. Regarding outcome measures, any measure evaluating adherence to medication was accepted,such as pharmacy records, electronic pillcontainers, andself-reported adherence.
employing the Cochran Q test and J2 statistic. Publication bias was assessed usingthe funnelplot and Egger test. To assess the possible effects of clinical heterogeneity in the meta-analysis results, subgroup analyses were performed according to the settingof the pharmacistdoing the intervention (community pharmacies or pharmacyservices in hospitals or primarycare centers),main adherence measure (pharmacy records,electronic pill container, or self-reported adherence), and type of diagnosis used for inclusion (only clinical or with a validated diagnostic instrument). Those subgroup analyses were pre-specified. Moreover, subgroup analyses were performedaccording to the analysis strategy (intent-to-treator per-protocol) as a means of assessing its effect on the results of the meta-analysis. Analyses were performed using Comprehensive Meta-Analysis, version 2, software (Biostat, Englewood, NJ). 
Results

LITERATURE SEARCH AND STUDY SELECTION
The electronic searchstrategyidentified438 potentially relevant papers, while 7 additional studies wereretrieved via the manual searchof citationindices and referencelists.In all, 50 were duplicatedtitles indexedin multipledatabases and wereexcluded. Of the 395 remaining studies, 367 were excluded by reviewing titleand abstract (221 described other interventions, the population in 78 was not depressed patients,63 were not RCTs, and 5 did not evaluate adherence) and 22 were excludedby reviewing full-text articles(7 did not evaluateadherence, 7 were not RCTs, 6 described other interventions, and 2 wereonly descriptive) ( Figure 1 ).In addition,correspondence wasconducted with the corresponding author of 1 article describing study methods thatmatched The quality of the studies was assessed independently by YLH and MRVusingtheJadad scale," The Jadad scaleis a 3-itemscalethat considers 3 features of a study: randomization, double-blinding,and flow of patients. Adequate descriptionof allocation concealmentwas also evaluated, so total summed scores ranged from 0 to 7, with'the higher scores indicating higher quality.22.24 However, blinding of pharmacists and participants was not possible because of the typeof intervention assessed in this meta-analysis; therefore, totalscoresrangedfrom 0 to 5. Inter-reviewer reliability for the quality of studies was measured by K statistics (0.958).
DATA ABSTRACTION AND QUANTITATIVE DATASYNTHESIS
By using a standardizedabstractionform, 2 reviewers(MRV and YLH) independentlyextractedkey features of the characteristics, methods, and outcomes of articles that met the inclusioncriteria. Key features included studydesign, periodof study, setting,samplesize, numberof pharmacists, intervention components, the main outcomemeasures reportedby the authors,and resultsand analysis strategy (ie, per-protocol or intent-to-treat). In the case of disagreement, a third reviewer(JGC) also checked the data and agreement was reached. Inter-reviewer reliability was measured by K statistics (0.910).
Dichotomous and continuous measures of the outcome were extracted. For continuous data, the standardized mean difference (SMD) was computedwith a 95% confidence interval. A random effects model was used.to calculate pooled odds ratios and 95% confidence intervals. Statistical We identified 6 studies for inclusionin the analysisthat assessed pharmacist interventions in patients initiating or maintaining a treatment with antidepressant medication (Table 1) . [26] [27] [28] [29] [30] [31] Overall, 1049 subjectswere randomized,527 (50.2%) of whom wererandomized to an intervention group and 522 (49.8%) to a control group. However, because of per-protocol analyses in some studies, results are reported for only 887 patients (84.9% of randomized patients), 459 (51.7%) belonging to theintervention groupand428 (483%) to thecontrol group. Most of the studies (4 of 6) werecarried out in the US,26.28,30 while the others were performed in the Netherlands" and in Australia," The studies werecarried out between 1998 and 2005 and the publication years ranged from2003 to 2006.There wereno significant baseline differences in sociodemographic characteristics betweenthe control and intervention groups. However, in 3 of the studies, baseline differences relatedto antidepressant medlcation'P" and clinical characteristics" were reported. In the study by Rickles et a1.,30 intervention participants were more likely than control participants to have a history of psychotropic medication use (41.9%vs 15.6%; P <0.05). In the study by Adler et a1.,27 intervention participants were more likely to have first used antidepressants more than a year before the initialquestionnaire (56.1% vs 452%; p < 0.05). Finally, in the studyby Capocciaet al.,28 more patients in the intervention group had been diagnosed with major depression at baseline than those in the control group (21% vs 9%; P < 0.05). However, in thecaseof the articles by Adleret al," and Capoccia et al.,28 statistical analyses were controlled for prior experience withantidepressants and baseline Structured Clin-icalInterview for DSM Disorders score,respectively, to minimizebias.
All patients had an established diagnosis of depression and were initiating (n = 658; 74.2%) or maintaining (n = 229; 25.8%) pharmacologic treatment with antidepressant drugs. In the study by Brook et al.," only patients taking nontricyclic antidepressants were considered for inclusion and in the study by Finley et a1.,26 96% of control patients and 88% of intervention patientswere prescribedselective serotonin reuptakeinhibitors. A totalof 3 different methods of assessing adherence to antidepressants were defined; self-reported adherence,26.28,30,31 pharmacy records,26,27~9,30 and electronic pill container,"
In 3 of the 6 studies,27,28,30 depression was diagnosed by means of validated diagnostic instruments basedon DSM-IV criteria, including the Primary Care Screener for Affective our criteria for selection. Results at 6-monthfollow-up were published, but no results werereported afterthattime," Even though we received a response fromtheauthor, data wereunavailable. 'One hundred nineteen (intervention = 51, control = 68) patients were randomized, but results were reported for the 106 patients who completed the 2-month assessment.
PTwenty-seven patients had been on antidepressant medication for less than 1 month at the beginning of the study.
Disorders, the PrimaryCare Evaluation of MentalDisorders, and the Beck Depression Inventory II. Baseline severity of depressionwas reported as being moderate to severe based on different measures (BeckDepression Inventory; Hopkins SymptomChecklist, BriefDepression Inventory, and KlO). While the follow-up period ranged from 2 to 12 months, in 4 of the studies it was 6 months. 26, 27, 29, 30 Where possible, data from 6 months were used to perform the analysis. 26.30 Communitypharmacists appliedthe intervention in 3 of the studies,29.31 and pharmacists from a pharmacy service of a primary caresetting performed it in theother3 studies. [26] [27] [28] In 1 case," information about the intervention was extracted from a previouspublication related to the study," In all 6 studiesthe intervention includedpatienteducationand monitoring.Other common interventionswere monitoring and managementof toxicity and adverse effects,26.30 adherence promotion,26,27,30,31 and provision of written or visual information. 26,29,31 In 2 of the studies 26 ,28 in which the intervention was conducted by a clinical pharmacist, the pharmacist could recommend or conduct changes or adjustments in medication.
Methodological quality ranged from 2 to 5 on the Jadad scale, and 4 of the studies scored 3 or more. 26, 27, 29, 30 The most commonly absent item was an adequate description of concealmentof allocation.
Intent-to-treat analyses were conducted in 3 of the 6 studies. 26 ,28,29 In the studyby Adleret al.," althoughit was stated that an intent-to-treat analysis was conducted, not allrandomized patients were includedin the analysis-only those with any 6-monthdata. That is to say,533 patientswere randomized, but informationwas given only for the 384 who completedthe 6-monthassessment. According to the Consolidated Standardsof ReportingTrials (CONSORT) guidelines," in order to preservefully the huge benefitof randomization, intent-to-treat analysis shouldincludeall randomized participantsin the analysis, who shouldall be retainedin the group to whichthey were allocated. Using this conservative definition of the intent-to-treat approximation analysis, we decided to classify the Adler et alP studyin the group of studiesthat conducted per-protocol analysisp, 30, 31 In 2 of the studies, some of the included patients were already on antidepressants at the time of enrollment.Fr" The study by Adler et alP reported results of patients initiating and maintaining treatmentwith antidepressants at the time of enrollment, while the information in the study by Crockett et al," was presented in aggregatedform, making it impossible to discern who was being initiated and who was being maintained on medication. For our meta-analysis, results from all patients were included, regardless of whether patients were initiating or maintaining pharmacologic treatment.In the study by Capocciaet al.,28 adherence information at 6-months of follow-up was used. In the study by Finley et al., 26 2 differentways of reportingadherence were employed: the Mean Possession Ratio and the percentage of adherent patients. In our meta-analysis, the percentageof adherentpatients at 6 months was used.
META-ANALYSIS
No significantheterogeneity was found between the included studies (Cochran Q =2.677; df =5; P =0.750; P <0.001; 't 2 <0.001). The pooled odds ratio demonstrated a significantbenefitfrom pharmacist interventions in the improvement of adherence to antidepressant pharmacologic treatment (1.639; 95% CI 1.236 to 2.174; p < 0.001) (Figure 2) .
When we compared the effectiveness of pharmacist intervention in depressed patients, after grouping by setting of pharmacy where the intervention was implemented (community pharmacy or pharmacy service), type of diagnosis (clinicalor validated psychiatric instrument),type of adherence measure (pharmacy records, electronic pill container,or self-reported), and analysisstrategy (per protocol or intent-to-treat), we observed that there were no significant differences, as confidence intervals from different subgroupsclearly overlapped (Figure 3) .
The funnel plot ofstandarderror against the natural logarithm of the odds ratio (Figure 4 ) and the Egger test for assessing bias (p = 0.460) suggested that there was little publication bias in the selectionof studies. The effect of removing 1 study each in turn was assessed and showed that statistically significant results did not depend on any of the individual studies. Cumulative meta-analysis was also performed, proving that the pooled estimate is robust over time.
Discussion
The results of our meta-analysis suggesta positiveeffect of pharmacist interventions on antidepressantuse in terms of patient adherence. These results are similar to those reported on collaborative care by Bower et al.'? that found a positiveeffect of collaborative care on patient adherenceto antidepressants (OR =1.92; 95% CI 1.54 to 2.39). Subgroup analysis showed no significant differences between groups when grouping by setting of pharmacy in which pharmacist conducted the intervention, type of diagnostic procedure, type of adherence measure, or analysis strategy used.
These results should be interpreted with the following limitations in mind. Firstly,althougha significant improvement in patient adherence to antidepressant medication was identified, it is unclear whether this will result in an improvement in depressive symptoms. However, previous studies have reported a positive association between improved antidepressant use and depressive symptoms, suggesting that the effects of collaborative care on symptoms of depression may be mediated through changes in adherence to antidepressants.v-" Secondly, the RCTs included were different in some methodologic approaches, such as the pharmacy setting in which the pharmacist performed the intervention, type of intervention performed, and type of diagnostic measures. In this respect, studies that considered different outcome measures were used, which could limit internal validity. Although no statistical heterogeneity was detected, the Cochran Q test has low power when the number of studies included in the meta-analysis is small and the J2 statistic also suffersfrom large uncertainty in this situation.
In a similar way, the power of the Egger test for assessing bias can also be affected by the low number of studies included.
Thirdly,a 6-month follow-up periodis a short time when referring to antidepressant treatment, whichshould be continued for at least6 monthsafterremission of an episodeof depression," However, it is well known that dropout occurs mostly at the beginning of treatment with antidepressants? Even thougha shortfollow-up period could have influenced the effectsizesof pharmacist intervention versus controls, the 2-monthtrial by Crockett et al," did not alter the results, as we confirmed in the robustness of analysis.
Fourthly,most studies were conductedin the US and the results may not generalize to other contexts. Finally,some baseline differences of the compared groups were identified in 3 of the studies,27,28,30 which could introduce bias. However,in 2 of these studies,27,28 statisticalmethodsto adjust for the baseline differences were used to minimize bias, while the third study" reached the highest score on Statistics for each study 
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The Annals of Pharmacotherapy • 2011 January, Volume 45 • 45 the Jadad scale and described an adequate randomization process and allocation concealment. In spite of these limitations, this study is, to the best of our knowledge, the first published systematic review and meta-analysis of pharmacist intervention in patients with depression. Analysis proved that the pooled estimate was robust and suggested that there was little publication bias.
Our review indicates that pharmacist interventions in the care of outpatients treated with antidepressants can significantly improve patient adherence to medication. Patient education and monitoring, along with monitoring and management of adverse effects and adherence promotion, were the most commonly reported interventions in both pharmacy service and community pharmacy. Two of the studies conducted in a pharmacy service also allowed pharmacists to recommend or conduct changes or adjustments in medication. However, no significant differences were found in terms of improvement of patient adherence to antidepressants when subgroup analyses were conducted by setting of pharmacist involved in the intervention.
Our review also indicates that the data generated from the published RCTs on pharmacist interventions in patients with depression are limited. Only 6 studies have been identified, implying that the power of some of the statistics used may be limited and it is possible that we have not been able to detect existent heterogeneity between studies or publication bias. Therefore, we would recommend more research in this area, mainly outside the US, to provide definite answers to the question we explored. Mtrooos:Se realize una revisi6n sistematica y meta-analisis de ensayos clfnicos aleatorizados (ECAs). LosECAsfueron identificados mediante busqueda en basesde datoselectr6nicas (MEDLINE, Central, lSI web of knowledge, y CSIC)desdesu origenhastaabrilde 2010,ademas se revisaron laslistas dereferencias y seconsult6 a expertos. Seseleccionaron aquellos ECAsqueevaluaban el impacto de intervenciones llevadas a caboporfarrnaceuticos paramejorar la adherencia a losantidepresivos en pacientes deprimidos en elentomo ambulatorio (fannacias comunitarlas o servicios de farmacia). Dosinvestigadores puntuaron la calidad de los estudios y extrajeron losdatossobrelascaracterfsticas delestudio y los resultados.
RESULTADOS: Se incluyeron seisECAs.Un totalde 887 pacientes con un diagn6stico establecido de depresi6n que iniciaban 0 mantenian un tratamiento farmaeol6gico conmedicaci6n antidepresiva y querecibieron unaintervenci6n farmaceutica (459pacientes) 0 el tratamiento habitual (428pacientes) fueron incluidos en la revisi6n. Las intervenciones mas frecuentemente descrltas fueron la monitorizaci6n y educaci6n del paciente, el controly rnanejo de la toxicidad y losefectos secundarios, la promoci6n del cumplirniento,la provisi6n de informaci6n visual 0 escrlta Yla recomendaci6n 0 implementaei6n de cambios y ajustes en la medicaci6n. En general, no se detectaron heterogeneidad estadfstica ni sesgos de publicaci6n. La oddsratioagregada, utilizando un modelede efectos aleatorios, fue de 1.64(95%CI 124 Y2.17).Losanalisis de subgrupos no detectaron diferencias estadfsticamente significativas en los resultados en funci6n deltipode farmaceutico involucrado, la medida de adherencia, la herramienta diagn6stica, 0 laestrategia de arnllisis.
CONCLUSIONES: Estosresultados sugieren que la intervenci6n del farmaceutico es eficazen la mejora de la adherencia a losantidepresivos. Sin embargo, estosdatosarin son limitados y recomendarfamos mas investigaci6n en estecampo,especialmente fuerade los EE.U.U.
Traducido porMaria Rubio-Valera L'Efficacite des Interventions du Pharrnaciensur I'Ameliorationde l'Adhesion aux Antidepresseurs: Revue Extensiveet Meta-Analyse
